Canaccord Genuity Downgrades Pacira Pharmaceuticals (PCRX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil drifts lower as Hormuz flows balance slow progress in Iran diplomacy
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- BioNTech ends colorectal cancer mRNA therapy trial early
Pacira Pharma (PCRX): Symphony Health Data Suggests Lower Q3 Revs - Jefferies
October 26, 2017 7:40 AM EDTJefferies analyst, David Steinberg, reiterated his Buy rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) and cut his price target to $57 from $59 after Symphony Health (SH) data indicates that Exparel achieved Sept sales of $21.5M (-6% M/M, -5% Y/Y).
The... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $57 at Jefferies
October 26, 2017 6:45 AM EDTJefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $57.00 (from $59.00) while maintaining a Buy rating.
Analyst Edward Chung remains positive on the name although Symphony Health data suggests lower Q3 revenues which drive the target cut.
... MoreJanney Montgomery Scott Downgrades Pacira Pharmaceuticals (PCRX) to Sell
October 26, 2017 6:43 AM EDTJanney Montgomery Scott downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Neutral to Sell.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $31.85 yesterday.
... More